Radiation plus two immunotherapy drugs shows promise for tough cancers
NCT ID NCT02639026
First seen Jan 05, 2026 · Last updated May 15, 2026 · Updated 21 times
Summary
This early-phase trial looked at combining a special type of radiation (hypofractionated radiotherapy) with two immunotherapy drugs (MEDI4736 and tremelimumab) for people with advanced melanoma, lung, breast, or pancreatic cancer that had spread. The main goal was to find the safest way to give this combination and to see how well patients tolerated it. 53 participants were enrolled to help determine the best dosing and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.